

Save a Cord. Save a Life.



2017 Year in Review

Save a Cord. Save a Life.

Banking for Life

A message from the Executive Director

Dear friends,

The Cleveland Cord Blood Center (CCBC) continues to provide stem cell-rich umbilical cord blood for transplants throughout the U.S. and around the globe, despite the more challenging healthcare landscape that transplant recipients faced in 2017.

Through 2017, we have collected more than 53,000 cord blood units in Cleveland, Atlanta and San Francisco, and processed and banked over 9,600 frozen cord blood units in Cleveland for clinical use. In addition, we have provided more than 8,400 research-grade cord blood units for research to investigators throughout the U.S.



As we mark our 10th anniversary in 2018, we look ahead to the opening of the CCBC Cellular Therapy Incubator, which is designed to capitalize on our experience with clinical products. Above all, we are deeply grateful to the cord blood donors, financial contributors, and our dedicated staff that help make our work possible, as well as our partners - including obstetric clinicians and staff, transplant clinicians and their teams, industry associates, the registries and colleagues that support our mission.

Save a Cord. Save a Life.



About the Cleveland Cord Blood Center

The Abraham J. and Phyllis Katz Cord Blood Foundation, dba Cleveland Cord Blood Center, is a non-profit organization that collects, processes, stores and distributes stem cell-rich umbilical cord blood, and conducts innovative medical research in cord blood cellular therapeutics. The cord blood, usually discarded at birth, is used for the treatment of deadly blood cancers and other life-threatening illnesses, and for medical research. As a non-controversial source of stem cells, cord blood is collected from umbilical cords after delivery of full-term, healthy infants.

The cord blood is then frozen and stored in liquid nitrogen freezers until needed. Thousands of cord blood stem cell transplants are performed worldwide each year and used in the treatment of leukemia and other blood disorders. Researchers are also looking at cord blood stem cells to treat other diseases such as diabetes, heart disease, metabolic diseases, neural disease or injury and more. Established in 2008, CCBC has been issued a biologics license from the U.S. Food and Drug Administration (FDA), is accredited by the Foundation for Accreditation of Cellular Therapy (FACT) and the American Association of Blood Banks (AABB), is designated as a Health Resources and Services Administration (HRSA) contractor, and is a member bank of the National Marrow Donor Program (NMDP).

Insights from Executive Team Members

Mary J. Laughlin, M.D. Founder and Medical Director

Since launching the Cleveland Cord Blood Center in 2008, I have witnessed the exponential growth of cord blood collections from caring and generous parents whose donations may ultimately be a lifesaving match for someone with blood cancer or other life-threatening disease. We have promoted promising medical research by CCBC scientists who are exploring cord blood treatments for diseases ranging from Type 1 Diabetes and wound healing to Parkinson's disease and HIV/ AIDS. The future holds tremendous potential for lifesaving and life-enhancing applications.



Wouter J. Van't Hof, Ph.D.
Cord Blood Bank Director/Processing Facility Director

We are in the midst of developing CCBC's Cellular Therapy Incubator (CTI), a state-of-the-art facility designed to host high-specialty programs for the advancement of new cord blood technologies and products. We look forward to the new opportunities CTI will provide CCBC through diversification and pipeline development of cord blood and cell therapy products, and by offering key services to therapy developers in the industry.


Lisa Phillips Johnson, B.S., MT(ASCP)SBB Quality and Regulatory Affairs Director

The Cleveland Cord Blood Center's FDA license for the manufacturing and distribution of HPC, Cord Blood (one of only seven nationally licensed cord blood banks), reflects a highly trained staff and dedication to meeting the highest standards in the industry for distribution of cord blood products. Accredited by FACT and AABB and designated as a HRSA public cord blood bank, we are committed in service to donating parents, along with transplant physicians and patients.



CLEVELAND CORD BLOOD CENTER | 2017 YEAR IN REVIEW

Parent Donations at the Heart of Our Work



Lyndsey Bengal: Cord blood donations save lives

When their daughter, Nora, was born at Hillcrest Hospital in 2015, Lyndsey Bengal and her husband, John, had already planned to donate their baby's umbilical cord blood to the Cleveland Cord Blood Center, a public cord blood bank. A few years before Nora's birth, the Kirtland, Ohio couple had witnessed the lifesaving benefits of umbilical cord blood stem cells when a close family member received a cord blood transplant from a sibling. When the cancer returned, a cord blood match was identified through the national Be The Match Registry, and a second cord blood transplant was performed.

As a clinical staff nurse on Labor & Delivery at Hillcrest Hospital, "Every patient that I care for and admit gets educated on cord blood banking. The question is a part of their admission assessment," she said.

Since Nora's birth, the couple donated their second daughter's cord blood to the public cord blood bank, and the family member who received the earlier cord blood transplant is a healthy teen. "It makes perfect sense to donate when you can potentially save someone's life."




CCBC adds west coast hospital partner




The Cleveland Cord Blood Center expanded umbilical cord blood collection to the west coast with the addition of Kaiser Permanente San Francisco earlier this year. The hospital became the first in the city to provide expectant parents with the opportunity to donate their babies' umbilical cord blood to a public cord blood bank.

Supported by a grant from California's Umbilical Cord Blood Collection Program, a CCBC-trained collection team collects and prepares the cord blood for shipment to the Northeast Ohio center. "Kaiser Permanente San Francisco will help further expand our diverse donor pool, and enhance our ability to help meet the growing global demand for umbilical cord blood matches," said Marcie Finney, Executive Director.



CLEVELAND CORD BLOOD CENTER | 2017 YEAR IN REVIEW


Cord Blood Distributed Throughout the U.S., Around the World through 2017



About 2017 Cord Blood Recipients

- Recipients ranged in age from 1 to 71
- Race of recipients: 64% Caucasian,
 9% African American,
 3% Native American, 1% Asian,
 22% Not reported
- Units distributed: in the U.S 85%; internationally – 15%
- Units collected have been used to treat a variety of diseases including:
- Acute lymphoblastic leukemia (ALL)
- Acute myelogenous leukemia (AML)
- Non-Hodgkin lymphoma
- Myelodysplastic/ myeloproliferative disorders
- Disorders of the immune system
- Inherited disorders of metabolism
- Severe aplastic anemia


CCBC Cord Blood Distributions Across the Globe (2008 to 2017)



A Path to Hope and Healing


Researchers Explore Cord Blood Treatment for Type 1 Diabetes

Approximately 1.25 million American children and adults have Type 1 Diabetes. Adolescents with Type 1 Diabetes do not have a normal number and function of Foxp3+ regulatory T cells (Tregs), a type of white blood cell that is a critical immune regulator to maintaining tolerance and limiting autoimmunity.



Cleveland Cord Blood Center researchers, under the direction of Jeong-su Do, Ph.D., are studying T cells from normal newborn babies' umbilical cord blood which are unique in their very strong T regulatory capacity that is related to immune tolerance between the baby and the mother during pregnancy. The CCBC researchers are applying the cell biology knowledge gained in investigating neonatal immune tolerance to the understanding of a baby's Tregs to treat patients with Type 1 Diabetes.

The CCBC researchers expect the Tregs to safely suppress the ongoing abnormal T cell attack on the patient's islet cells in the pancreas allowing beta cell recovery, and improvement or resolution of the disease.



Chris DeVine: A Cord Blood Recipient's Story

At the age of 24, Chris DeVine was diagnosed with lymphoma. A few years later, when his disease relapsed and he was diagnosed with leukemia, he learned that a cord blood transplant was his only treatment option when a bone marrow match could not be found.

Dr. Mary J. Laughlin, M.D., a pioneer in the cord blood transplantation field and founder of the Cleveland Cord Blood Center, performed the cord blood transplant. He now shares his experiences with others facing cancer. "I try to be as real as I can, answering questions and advising them to do what they feel is right for them."

Now in his 40s, Chris is an avid rock climber, snowboarder and guitarist who performs at local spots. In anticipation of the 20th anniversary of his cord blood transplant, he has grown his hair to donate for a wig to someone on their own journey to recovery.

CLEVELAND CORD BLOOD CENTER | 2017 YEAR IN REVIEW

CLEVELAND CORD BLOOD CENTER | 2017 YEAR IN REVIEW

Leadership

Mary J. Laughlin, M.D. Founder and Medical Director

Marcie R. Finney, M.S., MBA **Executive Director**

Wouter J. Van't Hof, Ph.D. Cord Blood Bank Director/Processing **Facility Director**

Lisa Phillips Johnson, B.S., MT(ASCP)SBB Quality and Regulatory Affairs Director



Save a Cord. Save a Life.

Board of Directors

Bruce Goodman Chairman

Alex Katz Treasurer

David Katz Secretary

Pablo Rubinstein, M.D. Mary J. Laughlin, M.D.



Supported by The Abraham J. and Phyllis Katz Foundation and Dr. Donald J. and Ruth Weber Goodman Philanthropic Fund

Cleveland Cord Blood Center

25001 Emery Road, Suite 150, Cleveland, Ohio 44128

Phone: 216-896-0360 | 866-922-3668 (1-866-922-DON8) | www.clevelandcordblood.org



Cleveland Cord Blood Center



Cleveland Cord Blood Center



@clevecordblood